TF, please not these old accusations again. Why would he initiate a P&D at the beginning of his tenure? Most unusual and extremely unlikely. The spike could have been caused by anything. Maybe shareholders and those having NexMed/APRI on the radar buying heavily after gaining hope due to an experienced CEO taking over business matters. Could be an overreaction of the market completely unrelated to a P&D scheme. And even if it was a P&D, this stock was an easy target for whoever wanted to take advantage of it.
I'm too lazy now to look at which events occured in this time frame which might have been responsible for the spike. Not sure if it really matters presently.
Also keep in mind that Damaj didn't pump the share price in 2016, particularly because he didn't sell any shares into the rally. He gave sensible guidance, deduced from the timely FDA approval of competitor products. Investors expect guidance. So what was he supposed to say if competitors received approval within 1 year or 2 at most? Would you have considered it more appropriate to guide investors by saying that approval was expected sometime in the next 4 years? Investors would run.
By the way, what did you find out about the "Contigent Consideration"? Is it related to predicted earn-out payments to Novalere? I can't really think of anything else right now.
